Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy.
Explore this paper's citation graph
Summary
Ranibizumab treatment resulted in DR improvements in all 3 baseline DR severity subsets examined, and the greatest benefits in DR improvement occurred in patients with baseline moderately severe to severe NPDR (DR levels 47/53).
- Type
- article
- Published
- 2018-10-01
- Cited by
- 92
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W2885579130
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:81182261
Keywords
Medicine, Diabetic retinopathy, Ranibizumab, Ophthalmology, Macular edema
References
- Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
- Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
- SEVERITY OF DIABETIC RETINOPATHY AND HEALTH-RELATED QUALITY OF LIFE: THE LOS ANGELES LATINO EYE STUDY
- Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
- Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
- VISUAL SIDE EFFECTS OF SUCCESSFUL SCATTER LASER PHOTOCOAGULATION SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Literature Review
- Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
- How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy.
- Anti-vascular endothelial growth factor therapy for diabetic macular edema
- Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.
- Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
- Diabetic Retinopathy and Diabetic Macular Edema
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial
- [Early photocoagulation of diabetic retinopathy].
- PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA: A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature
- The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
- Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab
- Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
Cited by
- Detection of Clinically Unsuspected Retinal Neovascularization with Wide-Field Optical Coherence Tomography Angiography
- Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy.
- Multiple Effects of Intravitreal Aflibercept on Microvascular Regression in Eyes with Diabetic Macular Edema.
- Advances in the treatment of diabetic retinopathy.
- Emerging Insights and Interventions for Diabetic Retinopathy
- Diabetic Retinopathy Preferred Practice Pattern®.
- Comparison of montage with conventional stereoscopic seven-field photographs for assessment of ETDRS diabetic retinopathy severity
- American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema
- Assessing the Severity of Diabetic Retinopathy: Early Treatment Diabetic Retinopathy Study Report Number 10.
- Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial.
- Quantitative assessment of the severity of diabetic retinopathy.
- Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials
- Diabetic Retinopathy and Related Clinical Practice for People with Diabetes in Korea: A 10-Year Trend Analysis
- Baseline Factors Associated with Diabetic Retinopathy Improvement in RIDE/RISE.
- Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
- Ultra-Response to Ranibizumab: Improvement by 4 or More Steps in Diabetic Retinopathy Severity in DRCR.net Protocol S.
- Modern principles of the diabetic macular edema management
- Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
- Self-Reported Awareness of Retinopathy Severity in Diabetic Patients
- Five-Year Patterns of Diabetic Retinopathy Progression in US Clinical Practice
Related papers
- Evaluation of the efficacy of ranibizumab for the treatment of diabetic macular edema in daily practice
- Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: 6-Month ROTATED Trial Results
- Real life gender related differences in patients with diabetic macular edema treated with ranibizumab
- Impact of baseline vitreomacular interface status on the treatment choice between aflibercept, bevacizumab or ranibizumab for diabetic macular edema
- Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
- Short-Term Outcomes of Switching Therapy from Bevacizumab Non-Responder to Ranibizumab in Diabetic Macular Edema
- Lucentis® (ranibizumab ophthalmic injection) for diabetic macular edema (DME)
- Ranibizumab in Diabetic Macular Edema; Level 1 and Level 2 Studies Findings